Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.
Richard R. Furman(Cornell University), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Liat Schwartz-Sagi, Jennifer R. Brown(Dana-Farber Cancer Institute), Deborah M. Stephens(University of North Carolina at Chapel Hill), John M. Pagel(University of Washington), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Simon Rule(AstraZeneca (United Kingdom)), Matthew Streetly(King's College - North Carolina), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Marshall Baek(AstraZeneca (United States)), Clare Sun(National Heart Lung and Blood Institute), Martin J.S. Dyer(University of Leicester), Paolo Ghia(Vita-Salute San Raffaele University), Michael Wang(St. Joseph Health System), Wojciech Jurczak(Jagiellonian University), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John C. Byrd(University of Cincinnati), Priti Patel(AstraZeneca (United States)), Susan O’Brien(University of California, Irvine)
Cited by 11
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k